Esperion Therapeutics Newsroom

Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6

Futu News02:31

Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham

Dow Jones01:44

Esperion Therapeutics Analyst Ratings

BenzingaDec 13 01:19

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsDec 12 23:31

Jefferies Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5

Futu NewsDec 12 00:32

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsDec 2 23:32

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsNov 26 23:32

Esperion Therapeutics Analyst Ratings

BenzingaNov 19 19:39

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsNov 19 19:31

A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16

Futu NewsNov 8 21:14

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating

Futu NewsOct 28 22:31

Esperion Therapeutics Analyst Ratings

BenzingaOct 2 22:48

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsOct 2 22:33

JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7

Futu NewsSep 3 23:32

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

BenzingaAug 13 01:57

Esperion Therapeutics Analyst Ratings

BenzingaAug 13 01:55

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating

Futu NewsJul 30 21:54

Esperion Therapeutics Analyst Ratings

BenzingaJun 28 23:10

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

BenzingaJun 28 23:09

Esperion Therapeutics Analyst Ratings

BenzingaJun 20 18:39